Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.

MLA

Fountzilas, George, et al. “Dose-Dense Sequential Adjuvant Chemotherapy Followed, as Indicated, by Trastuzumab for One Year in Patients with Early Breast Cancer: First Report at 5-Year Median Follow-up of a Hellenic Cooperative Oncology Group Randomized Phase III Trial.” BMC Cancer, vol. 14, July 2014, p. 515. EBSCOhost, https://doi.org/10.1186/1471-2407-14-515.

APA

Fountzilas, G., Dafni, U., Papadimitriou, C., Timotheadou, E., Gogas, H., Eleftheraki, A. G., Xanthakis, I., Christodoulou, C., Koutras, A., Papandreou, C. N., Papakostas, P., Miliaras, S., Markopoulos, C., Dimitrakakis, C., Korantzopoulos, P., Karanikiotis, C., Bafaloukos, D., Kosmidis, P., Samantas, E., … Dimopoulos, M.-A. (2014). Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer, 14, 515. https://doi.org/10.1186/1471-2407-14-515

Chicago

Fountzilas, George, Urania Dafni, Christos Papadimitriou, Eleni Timotheadou, Helen Gogas, Anastasia G Eleftheraki, Ioannis Xanthakis, et al. 2014. “Dose-Dense Sequential Adjuvant Chemotherapy Followed, as Indicated, by Trastuzumab for One Year in Patients with Early Breast Cancer: First Report at 5-Year Median Follow-up of a Hellenic Cooperative Oncology Group Randomized Phase III Trial.” BMC Cancer 14 (July): 515. doi:10.1186/1471-2407-14-515.